Rx for Alzheimer's
Rx for Alzheimer's: What’s Working, What’s Not, and What’s in the Pipeline
The year 2025 was full of breakthroughs, debates, and big questions in Alzheimer’s research. One event that shaped many of these conversations? The Clinical Trials on Alzheimer’s Disease (CTAD) Conference. It may not have been on everyone’s radar, but its impact was undeniable.
In this special episode, Penn Memory Center Co-Directors Dr. Jason Karlawish and Dr. David Wolk share what stood out at CTAD, what’s changing in the field, and what to watch next.
Inside this episode:
Anti-amyloid therapies update: Where things stand with lecanemab and donanemab, and what the next generation of these drugs could look like
GLP-1 disappointment: Why Novo Nordisk’s semaglutide trials for Alzheimer’s disease came up short
Lifestyle interventions: The latest findings from the POINTER Study and what they mean for brain health
Resources available on the episode webpage linked below
Visit CTAD’s website
More information on anti-amyloid therapies
Novo Nordisk’s announcement of negative results “EVOKE” and “EVOKE+” trials
More information on the POINTER Study